(redirected from corticotropin-releasing hormone)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to corticotropin-releasing hormone: CRH, Corticotropin-releasing factor
References in periodicals archive ?
Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration: a new test to distinguish Cushing's syndrome from pseudo-Cushing's states.
Androgen inhibits the increases in hypothalamic corticotropin-releasing hormone (CRH) and CRH-immunoreactivity following gonadectomy.
Fuchs E, Flugge G: Modulation of binding sites for corticotropin-releasing hormone by chronic psychological stress.
The hypothalamus (as well as other regions of the brain) secretes a hormone known as CRH, for corticotropin-releasing hormone.
Glucocorticoid hormones, which are often used to treat inflammatory illnesses like rheumatoid arthritis, asthma, or ulcerative colitis, block the release of both corticotropin-releasing hormone (CRH) and ACTH.
One such effect is to stimulate the skin to synthesize corticotropin-releasing hormone, a hypothalamic hormone that has immunomodulatory activity.
The concentrations of mRNA for corticotropin-releasing hormone (CRH) in maternal plasma are significantly higher in PE than in controls (5), but no demonstration of relationships with gestational age and/or severity of PE have been reported.
For the mRNA target, we chose the mRNA of the corticotropin-releasing hormone (CRH) [3] locus, which is known to be expressed in the placenta (18) and is released into the maternal circulation (19, 20).
Nonetheless, our data open up the possibility of predicting preeclampsia using maternal plasma fetal DNA, especially when used with other biochemical markers such as corticotropin-releasing hormone, [alpha]-fetoprotein, inhibin A, and activin A (16, 17).
Of the samples used for the method comparison, 356 were obtained from 89 patients during corticotropin-releasing hormone (CRH) stimulation testing.
Steroids, corticotropin-releasing hormone, ACTH and prostaglandin interactions in the amnion and placenta of early pregnancy in man.
The amount of fetal DNA was measured by a TagMan[R] real-time PCR assay for a Y-chromosome-specific sequence (SRY) (17), whereas the presence of fetal mRNA was quantified by a similar quantitative reverse transcription-PCR (RT-PCR) assay for the corticotropin-releasing hormone (CRH) gene, which is known to be expressed in the placenta (18).
Increased concentrations of mRNA for corticotropin-releasing hormone, which is synthesized in the placenta, are seen in the blood of patients affected by preeclampsia (3), and panels of mRNAs (4) can be used to test for a disease of interest.
When he injected a synthetic version of corticotropin-releasing hormone (CRH) into the tadpoles, their thyroid hormones increased and metamorphosis proceeded faster than normal.
The presence of circulatory placentally derived fetal mRNA was assayed by a real-time reverse transcriptionPCR assay for corticotropin-releasing hormone (CRH) mRNA transcripts as described previously (7, 9) (see Table 1 in the online Data Supplement).
Full browser ?